K-111 (BM-170744) is an orally active PPARα agonist used in the research of type 2 diabetes, dyslipidemia, obesity, and metabolic syndrome; it exhibits efficacy in improving insulin resistance, reducing body weight, and ameliorating atherogenic dyslipidemia.